Clinical Trial Update: Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma [Phase 1, Phase 2]

View source ↗

Summary

This ClinicalTrials.gov entry reports a Phase 1/Phase 2 study evaluating the combination of apatinib and irinotecan for recurrent high-grade glioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Glioma

Drugs mentioned

• Apatinib (apatinib)
• Irinotecan (Irinotecan)

Snippet

Sponsor: The First People's Hospital of Lianyungang | Conditions: High-grade Glioma | Phase 1, Phase 2 | Status: UNKNOWN